Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 24;8(7):e126.
doi: 10.1002/hem3.126. eCollection 2024 Jul.

The role of trephine bone marrow biopsies in the era of measurable residual disease - Results from the CLL10 trial of the German CLL Study Group (GCLLSG)

Nadine Kutsch  1 , Sandra Robrecht  1 , Anna Fink  1 , Elisabeth Lange  2 , Rudolf Weide  3 , Michael G Kiehl  4 , Martin Sökler  5   6 , Rudolf Schlag  7 , Ursula Vehling-Kaiser  8 , Georg Köchling  9 , Christoph Plöger  10 , Michael Gregor  11 , Torben Plesner  12 , Michael R Clausen  12 , Ilske Oschlies  13 , Matthias Ritgen  14 , Marco Herling  1   15 , Kirsten Fischer  1 , Hartmut Döhner  16 , Clemens-Martin Wendtner  17 , Karl-Anton Kreuzer  1 , Stephan Stilgenbauer  6   15 , Michael Hallek  1 , Sebastian Böttcher  18 , Wolfram Klapper  13 , Barbara Eichhorst  1
Affiliations

The role of trephine bone marrow biopsies in the era of measurable residual disease - Results from the CLL10 trial of the German CLL Study Group (GCLLSG)

Nadine Kutsch et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Nadine Kutsch: Honoraria: AbbVie, AstraZeneca, BMS, Kite/Gilead; Research support: AstraZeneca, Gilead. travel grants: AbbVie, AstraZeneca, Beigene, Celgene, Janssen. Sandra Robrecht: Honoraria: AstraZeneca. Anna Fink: Research funding: AstraZeneca and Celgene, Travel grants: AbbVie. Elisabeth Lange: no COIs. Rudolf Weide: Personal fees from AstraZeneca, BeiGene, Biotest, CSL Behring, Daiichi Sankyo, Eisai, Gilead, Hexal, Incyte, Medac, Menarini‐Stemline, Pierre Fabre, Roche, SeaGen, Sobi, and Takeda. Our institution has received research funding from Amgen, Biotest, Celgene, CSL Behring, Daiichi Sankyo, Eisai, GSK, Hexal, Lilly, Medac, Mundipharma, Octapharma, Sobi, and Takeda. Michael G. Kiehl: no COIs. Martin Sökler: no COIs. Rudolf Schlag: no COIs. Ursula Vehling‐Kaiser: no COIs. Georg Köchling: no COIs. Christoph Plöger: no COIs. Michael Gregor: no COIs. Torben Plesner: advisory board: Celgene/BMS. Michael R. Clausen: no COIs. Ilske Oschlies: no COIs. Matthias Ritgen: grants from F. Hoffman‐La Roche; and personal fees from F. Hoffmann‐La Roche and AbbVie. Marco Herling: no COIs. Kirsten Fischer: Advisory Board: AbbVie, Roche, AstaZeneca, Honoraria: Roche, AstraZeneca, Travel Support: Roche. Hartmut Döhner: Advisory role with honoraria for AbbVie, AstraZeneca, Gilead, Janssen, Jazz, Pfizer, Servier, Stemline, Syndax; clinical research funding (to institution) from AbbVie, Astellas, Bristol Myers Squibb, Celgene, Jazz Pharmaceuticals, Kronos Bio, Servier. Clemens‐Martin Wendtner: Research grants, advisory boards and travel grants by Hoffmann‐La Roche, Janssen‐Cilag, AstraZeneca, AbbVie, BeiGene and GSK. Karl‐Anton Kreuzer: consultant or advisory board member, honoraria and research support by AbbVie, Amgen, F. Hoffmann‐LaRoche, Gilead, Janssen‐Cilag and Mundipharma. Stephan Stilgenbauer: Advisory board, honoraria, research support, travel support, speaker fees, trial participation: AbbVie, Amgen, AstraZeneca, BeiGene, BMS, Celgene, Gilead, GSK, Hoffmann‐La Roche, Janssen, Lilly, Novartis, Sunesis. Michael Hallek: Consultant or advisory board member, honoraria, and research support by AbbVie, Amgen, Celgene, F. Hoffmann‐LaRoche, Gilead, Janssen‐Cilag and Mundipharma. Sebastian Böttcher: research funding from Janssen and AbbVie; and honoraria from Roche, Janssen, AbbVie, Novartis, Becton Dickinson, AstraZeneca, and Sanofi. Wolfram Klapper: Research grants from Roche, Amgen, Janssen, InCyte Regeneraon, Takeda and advisory role (Roche) paid to my institution. All without relevance for the current manuscript. Barbara Eichhorst: Consultant or advisory board member, research support or travel support by AbbVie, AstraZeneca, Celgene, F. Hoffmann‐LaRoche, Gilead, Janssen‐Cilag.

Figures

Figure 1
Figure 1
(A) Landmark progression‐free survival (PFS) and overall survival (OS) according to bone marrow (BM) infiltration by IHC and MRD in BM, analysis population restricted to patients with BM infiltration assessed in central laboratory. (B) Landmark PFS and OS according to BM infiltration by IHC and MRD in PB (analysis population restricted to patients with BM infiltration assessed in central laboratory). (C) Landmark PFS and OS according to BM infiltration by IHC and laboratory (central vs. local). (D‐MRD, detectable MRD; PB, peripheral blood; IHC−, no BM infiltration by IHC; IHC+, with BM infiltration by IHC; U‐MRD = MRD < 10−4).
See this image and copyright information in PMC

References

    1. Eichhorst B, Niemann CU, Kater AP, et al. First‐line venetoclax combinations in chronic lymphocytic leukemia. N Engl J Med. 2023;388(19):1739‐1754. - PubMed
    1. Fischer K, Al‐Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225‐2236. - PubMed
    1. Seymour JF, Kipps TJ, Eichhorst BF, et al. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed‐duration venetoclax‐rituximab. Blood. 2022;140(8):839‐850. - PMC - PubMed
    1. Al‐Sawaf O, Zhang C, Lu T, et al. Minimal residual disease dynamics after venetoclax‐obinutuzumab treatment: extended off‐treatment follow‐up from the randomized CLL14 study. J Clin Oncol. 2021;39(36):4049‐4060. - PMC - PubMed
    1. EMA . Accessed April 8, 2023. https://www.ema.europa.eu/en/documents/scientific-guideline/evaluation-a...

LinkOut - more resources